<!doctype html public "-//W3C//DTD W3 HTML//EN">
<html><head><style type="text/css"><!--
blockquote, dl, ul, ol, li { padding-top: 0 ; padding-bottom: 0 }
--></style><title>CIMIT Forum Tuesday April 17, 2007: Lester Wolfe
Workshop</title></head><body>
<div><br></div>
<div><br></div>
<div><font size="+1" color="#008080"><i><b>Please Join Us at the CIMIT
Forum / Lester Wolfe Workshop...</b></i></font></div>
<div><br></div>
<div><font size="-1"><b>Tuesday, April 17, 2007</b></font></div>
<div><font size="-1"><b>4:00-6:00pm</b></font></div>
<div><font size="-1"><b>REFRESHMENTS at 3:30pm</b></font></div>
<div><font size="-1"><b>Location: Massachusetts General Hospital,
Richard B. Simches Research Center, Room 3110, 185 Cambridge St,
Boston</b></font></div>
<div><font size="-1">Directions to MGH and Richard B. Simches Research
Center:</font> <a href="http://www.cimit.org/directions.html"><font
size="-1" color="#0000FF"><u>
http://www.cimit.org/directions.html</u></font></a></div>
<div><font size="-1">Map of MGH Campus:</font> <a
href="http://www.cimit.org/documents/SimchesMap.pdf"><font size="-1"
color="#0000FF"><u>
http://www.cimit.org/documents/SimchesMap.pdf</u></font></a></div>
<div><font size="-1">Note: You will need to check in with Security
upon entering the Simches Research Center. PHS employees, please bring
your identification badges. All others will be provided temporary
badges.</font></div>
<div><br></div>
<div><font size="-1"><b>Lester Wolfe Workshop in Laser Biomedicine:
Optical Methods in Breast Cancer</b></font></div>
<div><br></div>
<div><font size="-1">Early diagnosis, management and therapy of breast
cancer are important problems, and there is interesting science as
well. Optical methods hold much promise. The Workshop will begin with
an overview, to be followed by presentations of optical methodologies
in forefront areas. Sponsored by the MIT G.R. Harrison Spectroscopy
Laboratory, Massachusetts General Hospital Wellman Center for
Photomedicine; Harvard-MIT Division of Health Sciences and Technology
and Center for Integration of Medicine and Innovative Technology
(CIMIT). Click here to read about Lester Wolfe:</font> <a
href="http://web.mit.edu/spectroscopy/events/wolfe.html"><font
size="-1" color="#0000FF"><u>
http://web.mit.edu/spectroscopy/events/wolfe.html</u></font></a></div>
<div><br></div>
<div><font size="-1"><b>Moderator:<i> Michael Hamblin, PhD,</i></b><i>
Associate Professor, Wellman Center for Photomedicine,
MGH</i></font></div>
<div><font size="-1"><b>Introduction and Clinical
Overview</b></font></div>
<div><font size="-1"><i><b>Barbara L. Smith</b>, MD, PhD, Director,
Breast Program of the Cancer Center and Co-Director of the Women’s
Cancers Program, Massachusetts General Hospital; Assistant Professor
of Surgery, Harvard Medical School and MGH; Chief of Breast Surgical
Services, Gillette Centers for Women’s Cancers, Dana-Farber Cancer
Institute</i></font></div>
<div><br></div>
<div><font size="-1"><b>Shedding Light on Breast Cancer: Advances in
Optical Spectroscopy Diagnosis of Breast Cancer</b></font></div>
<div><font size="-1"><i><b>Maryann Fitzmaurice</b>, MD, PhD, Associate
Professor of Pathology and Oncology, Case Western Reserve
University</i></font></div>
<div><font size="-1">Despite recent clinical advances, there remain
challenges to early diagnosis and effective therapy of breast cancer.
Among these are mammographic “false positives” (mammographically
suspect lesions that are benign on biopsy) and operative “false
negatives” (positive margins missed at breast cancer surgery that
necessitate re-operation for complete resection). Optical spectroscopy
holds promise for both improving the accuracy of breast cancer
diagnosis and enabling breast cancer diagnosis to be made in a less
invasive and more timely fashion. Recent work on the optical
spectroscopy of breast cancer will be reviewed, and results presented
for<i> ex vivo</i> pre-clinical studies using a multi-modality
technique that combines diffuse reflectance, fluorescence and Raman
spectroscopy to provide more robust spectroscopic breast cancer
diagnosis.</font></div>
<div><br></div>
<div><font size="-1"><b>Breast Imaging and Characterization with
Diffuse Optics</b></font></div>
<div><font size="-1"><i><b>Arjun Yodh</b>, PhD, James M. Skinner
Professor of Science, Department of Physics & Astronomy,
University of Pennsylvania</i></font></div>
<div><font size="-1">This talk is oriented towards functional imaging
and spectroscopy of breast cancer. Professor Arjun Yodh will focus on
several recent studies, summarize the tumor contrast results obtained
in a pilot clinical investigation employing diffuse optical tomography
(DOT), and discuss the next generation instrument. He will present
first in-vivo<i> fluorescence</i> diffuse optical tomography (FDOT) of
breast cancer, describe the measurement of tumor blood flow and
oxygenation of breast cancer during chemotherapy, and, if time
permits, present multi-modal measurements combining DOT with positron
emission tomography (PET).</font></div>
<div><br></div>
<div><font size="-1"><b>Intra-operative Optical Biopsy of Breast
Cancer</b></font></div>
<div><font size="-1"><i><b>Stephen Boppart</b>, MD, PhD, Director,
Mills Breast Cancer Institute, Carle Foundation Hospital; Associate
Professor, Electrical Engineering, Bioengineering, and Medicine,
University of Illinois at Urbana-Champaign</i></font></div>
<div><br></div>
<div><font size="-1">Traditionally, the microscopic evaluation and
diagnosis of tissue biopsy specimens has occurred remote from the
point-of-care, since tissue processing, sectioning, and staining must
be performed. Coherent optical imaging techniques such as optical
coherence tomography (OCT) enable real-time intra-operative
visualization of tissue architecture at cellular resolution, with the
potential to perform volumetric microscopy and computer-automated
classification over large regions. OCT has been used intraoperatively
to assess margin status of lumpectomy specimens, and to assess lymph
nodes for evidence of metastases. Fiber-optic beam delivery within
needle probes facilitates guiding needle biopsies of breast masses.
These methods enable real-time, point-of-care feedback during surgical
procedures and interventions in the treatment of breast
cancer.</font></div>
<div><br></div>
<div><font size="-1"><i>Click here to learn more about the CIMIT
Forum:</i></font> <a
href="file://www.cimit.org/forum/current.html"><font size="-1"
color="#0000FF"><u>
www.cimit.org/forum/current.html</u></font></a></div>
<div><br></div>
<div><font size="-1">Note: There is no registration required to attend
the weekly CIMIT Forum.</font></div>
<div><br></div>
<div><font size="-1">CIMIT (Center for Integration of Medicine and
Innovative Technology) is a catalyst for the application of technology
to healthcare. The focus is to bring together scientists and engineers
working at the frontiers of high technology with clinicians who are at
the forefront of medicine. The goal of the CIMIT Forum is to promote
the exchange of ideas and information between diverse communities and
to provide an arena where interdisciplinary discussion can lead to
breakthroughs in biomedical engineering and ultimately patient care.
Dialogue is an important part of opening doors for education and
collaboration. The audience is a diverse group of practitioners and
researchers, including clinicians, engineers, educators, scientists,
administrators and students. For more information about Tuesday's
Forum, visit</font> <a
href="file://www.cimit.forum/current.html"><font size="-1"
color="#0000FF"><u> www.cimit.forum/current.html</u></font></a><font
size="-1"> or contact DeAnna Grosbaum, dgrosbaum@partners.org,
617-726-0797.</font></div>
<div>The information transmitted in this electronic communication is
intended only for the person or entity to whom it is addressed and may
contain confidential and/or privileged material. Any review,
retransmission, dissemination or other use of or taking of any action
in reliance upon this information by persons or entities other than
the intended recipient is prohibited. If you received this information
in error, please contact the Compliance HelpLine at 800-856-1983 and
properly dispose of this information.</div>
<div><br></div>
</body>
</html>